Meth addiction recovery is happening in a system where risk and support move in lockstep, yet the odds are often stacked against people who need the most help. One analysis estimates people with methamphetamine use disorder plus depression face a 2.0x higher risk of relapse than those without depression, while outpatient contingency management and other behavioral treatments are among the few approaches showing consistent improvements in outcomes. Meanwhile, recovery capacity has to stretch across stimulant and opioid co-use realities, including millions of overdose-linked emergency responses and major federal funding efforts, making the statistics a practical map for what works and what still falls short.
Key Takeaways
- 2.0x higher risk of relapse among people with methamphetamine use disorder who have co-occurring depression compared with those without depression, based on a meta-analytic estimate across observational studies.
- 1.5x to 2.0x higher odds of HIV infection among people who inject drugs who use methamphetamine compared with those who do not, based on pooled estimates reported in a systematic review.
- The National Institute on Drug Abuse (NIDA) reports that effective behavioral treatments for methamphetamine use disorder can produce clinically meaningful reductions in use compared with control conditions, with effect sizes reported across trials (meta-analytic summary).
- 2.3% of US adults reported past-year substance use disorder treatment need in the 2020–2022 period; among those needing help, a measurable share reported trouble accessing treatment.
- 8.4% of Americans aged 18+ with substance use disorder reported receiving medication-assisted treatment for opioid use disorder (where applicable), illustrating cross-need planning because meth recovery often coincides with other SUD treatment needs.
- In a 2021 study of recovery coaching for substance use disorder, participants had higher odds of attending follow-up appointments compared to controls, with odds ratios reported.
- In 2022, the US recorded 81,806 opioid-related overdose deaths; while opioid-specific, it co-occurs with stimulant use patterns relevant to comprehensive recovery.
- More than 100,000 drug overdose deaths occurred in the US in 2022 (CDC/NCHS), setting the upper-bound risk environment for stimulant-related recovery services.
- WHO’s Global Health Estimates report that 296,000 deaths in 2019 were attributed to drug use (broad drug categories), framing recovery urgency including meth-related harm reduction needs.
- $1,000,000,000+ spent annually in the US on substance use disorder treatment services and related programs is evidenced by SAMHSA funding and federal appropriation totals for behavioral health/substance use programming in recent federal budgets (substance-use treatment appropriations).
- $1.6 billion allocated to SAMHSA for substance use disorder-related activities in FY 2024 (as reported in SAMHSA’s budget documents).
- The State Opioid Response (SOR) program awarded $2.0 billion in funding to states/territories under the 2018–2023 timeline; diversion of capacity and overlap with stimulant recovery planning is reflected in state recovery infrastructure needs.
- Substance use disorder treatment workforce turnover was reported at 31% in a survey of addiction treatment providers in the US, affecting continuity of care critical to recovery.
- The US Bureau of Labor Statistics reported about 1.8 million people employed in community and social services occupations in 2023, a labor pool relevant to treatment staffing capacity.
- The National Academies of Sciences report on ‘Medications and Behavioral Health Interventions for Methamphetamine Use Disorder’ concludes there are currently no FDA-approved medications for methamphetamine use disorder, framing reliance on behavioral recovery services; the report includes a clear quantified statement of the current medication status.
People with meth use disorder face higher relapse and HIV risks, but contingency management and behavioral care improve outcomes.
Related reading
01 · Category
Health Outcomes15 stats
01
2.0x higher risk of relapse among people with methamphetamine use disorder who have co-occurring depression compared with those without depression, based on a meta-analytic estimate across observational studies.
02
1.5x to 2.0x higher odds of HIV infection among people who inject drugs who use methamphetamine compared with those who do not, based on pooled estimates reported in a systematic review.
03
The National Institute on Drug Abuse (NIDA) reports that effective behavioral treatments for methamphetamine use disorder can produce clinically meaningful reductions in use compared with control conditions, with effect sizes reported across trials (meta-analytic summary).
04
A 2019 randomized trial of contingency management for stimulant use disorder reported a clinically significant increase in stimulant-negative urine samples relative to usual care, with effects persisting during treatment windows.
05
Contingency management for stimulant use disorder is supported by evidence syntheses showing consistent improvements in abstinence outcomes; one meta-analysis reported that contingency management increased treatment retention compared with control conditions.
06
Matrix Model behavioral treatment for substance use disorders shows reductions in drug use among participants in trials; pooled evidence indicates improved outcomes versus standard care for methamphetamine users in substance-focused programs.
07
A 2021 Cochrane Review evaluating psychosocial interventions for methamphetamine use disorder found some interventions improved outcomes such as retention and drug use measures compared with controls, though evidence quality varied.
08
A 2016–2020 synthesis reported that cognitive behavioral therapy (CBT) can reduce methamphetamine use among trial participants versus comparator conditions, with magnitude varying by study.
09
A 2020 study of contingency management implementation reported that reinforcement schedules are associated with higher abstinence rates in real-world settings compared with non-contingent approaches.
10
In the US, MAT for opioid use disorder is associated with reduced mortality; this cost context is used in recovery planning because meth users often present with polysubstance needs—peer-reviewed estimates quantify mortality reduction by MAT.
11
A 2020 systematic review of psychosocial interventions for stimulant use disorder found contingency management had one of the strongest evidence bases for improving abstinence outcomes (with quantitative synthesis effects).
12
A 2018 longitudinal study reported that longer time-in-treatment is associated with lower meth use over follow-up, with a quantified relationship between retention duration and outcomes.
13
In a trial of behavioral therapy for methamphetamine use disorder, participants randomized to an intensive behavioral approach had a higher proportion achieving negative drug tests than those receiving standard counseling, with effect reported as a percentage difference.
14
A 2024 observational study reported that people receiving contingency management in outpatient settings showed improved treatment retention rates compared with standard care, quantified in the study’s retention statistics.
15
NIDA states that contingency management yields improved outcomes; a cited meta-analysis reports standardized mean differences in abstinence-related outcomes compared with control across included studies.
Interpretation
Health Outcomes Interpretation
Across Health Outcomes, the evidence suggests that targeted behavioral care can materially improve recovery, with contingency management and other psychosocial treatments repeatedly linked to better abstinence and retention while also lowering relapse risk, which matters given the 2.0x higher relapse risk seen when methamphetamine use disorder co-occurs with depression.
02 · Category
Access & Coverage5 stats
01
2.3% of US adults reported past-year substance use disorder treatment need in the 2020–2022 period; among those needing help, a measurable share reported trouble accessing treatment.
02
8.4% of Americans aged 18+ with substance use disorder reported receiving medication-assisted treatment for opioid use disorder (where applicable), illustrating cross-need planning because meth recovery often coincides with other SUD treatment needs.
03
In a 2021 study of recovery coaching for substance use disorder, participants had higher odds of attending follow-up appointments compared to controls, with odds ratios reported.
04
In a 2019 health services study, integrated behavioral health models reduced no-show rates by a measurable percentage compared with usual referral processes, relevant to improving continuity for stimulant recovery.
05
In the US, SAMHSA reports that 2023 had 1,000+ National Helpline contacts per day on average at peak reporting windows, illustrating recovery demand intensity (averaged numeric operational reporting).
Interpretation
Access & Coverage Interpretation
With only 2.3% of US adults reporting past-year substance use disorder treatment need in 2020–2022 and 8.4% of adults with substance use disorder receiving medication-assisted treatment for opioid use disorder, the data point to a clear Access and Coverage gap where people often need help but coverage and linkage to ongoing services remain uneven, reflected in high demand for support as shown by SAMHSA’s 1,000-plus National Helpline contacts per day at peak in 2023.
03 · Category
Public Health Burden6 stats
01
In 2022, the US recorded 81,806 opioid-related overdose deaths; while opioid-specific, it co-occurs with stimulant use patterns relevant to comprehensive recovery.
02
More than 100,000 drug overdose deaths occurred in the US in 2022 (CDC/NCHS), setting the upper-bound risk environment for stimulant-related recovery services.
03
WHO’s Global Health Estimates report that 296,000 deaths in 2019 were attributed to drug use (broad drug categories), framing recovery urgency including meth-related harm reduction needs.
04
The US CDC’s National Syndromic Surveillance Program records stimulant-related emergency department visit trends; ED syndromic signals provide numeric time series used to track rising acute harm risk.
05
Naloxone distribution and overdose response systems (not meth-specific) show millions of doses dispensed in the US in recent years, supporting emergency linkage for stimulant co-use overdoses.
06
In 2019, the Global Burden of Disease estimated that drug use disorders accounted for 0.2% of global DALYs; while not meth-only, it quantifies stimulant-related recovery system scale needs.
Interpretation
Public Health Burden Interpretation
With the US seeing 100,000-plus overdose deaths in 2022 and 81,806 opioid-related overdose deaths alongside co-occurring stimulant patterns, the public health burden for meth addiction recovery is amplified by a high-risk overdose environment where emergency and harm reduction services must be ready for acute stimulant-related harm.
More related reading
04 · Category
Program & Costs7 stats
01
$1,000,000,000+ spent annually in the US on substance use disorder treatment services and related programs is evidenced by SAMHSA funding and federal appropriation totals for behavioral health/substance use programming in recent federal budgets (substance-use treatment appropriations).
02
$1.6 billion allocated to SAMHSA for substance use disorder-related activities in FY 2024 (as reported in SAMHSA’s budget documents).
03
The State Opioid Response (SOR) program awarded $2.0 billion in funding to states/territories under the 2018–2023 timeline; diversion of capacity and overlap with stimulant recovery planning is reflected in state recovery infrastructure needs.
04
A 2023 cost-effectiveness analysis found that contingency management can be cost-effective relative to usual care for stimulant use disorder from a healthcare payer perspective, using QALY or cost per outcome metrics reported in the paper.
05
A 2022 evaluation of contingency management in outpatient stimulant treatment estimated reduced healthcare utilization attributable to improved outcomes, reported as cost savings in the study’s economic analysis.
06
SAMHSA’s Certified Community Behavioral Health Clinics (CCBHC) demonstration evaluated improvements in access and reduced emergency department use; the evaluation reports numeric changes in service utilization after implementation.
07
In the CCBHC evaluation, after implementation, patients receiving CCBHC services had higher rates of follow-up contact and reduced ED use, reported as percentages in the published report.
Interpretation
Program & Costs Interpretation
For the Program and Costs angle, the federal push is clearly large and sustained, with $1.6 billion allocated to SAMHSA for substance use disorder activities in FY 2024 and $2.0 billion awarded to states through the State Opioid Response from 2018 to 2023, while evaluations like CCBHC show that targeted programs can translate into measurable reductions in emergency department use.
05 · Category
Workforce & Capacity2 stats
01
Substance use disorder treatment workforce turnover was reported at 31% in a survey of addiction treatment providers in the US, affecting continuity of care critical to recovery.
02
The US Bureau of Labor Statistics reported about 1.8 million people employed in community and social services occupations in 2023, a labor pool relevant to treatment staffing capacity.
Interpretation
Workforce & Capacity Interpretation
With workforce turnover in substance use disorder treatment at 31%, providers face a continuity-of-care challenge, even though the US had about 1.8 million people employed in community and social services in 2023 to support recovery capacity.
06 · Category
Industry Trends1 stats
01
The National Academies of Sciences report on ‘Medications and Behavioral Health Interventions for Methamphetamine Use Disorder’ concludes there are currently no FDA-approved medications for methamphetamine use disorder, framing reliance on behavioral recovery services; the report includes a clear quantified statement of the current medication status.
Interpretation
Industry Trends Interpretation
The National Academies report notes that as of now there are no FDA approved medications for methamphetamine use disorder, reinforcing an industry trend toward leaning primarily on behavioral recovery services rather than drug based treatment.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Meth Addiction Recovery Statistics. Gitnux. https://gitnux.org/meth-addiction-recovery-statistics
MLA
Stefan Wendt. "Meth Addiction Recovery Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/meth-addiction-recovery-statistics.
Chicago
Stefan Wendt. 2026. "Meth Addiction Recovery Statistics." Gitnux. https://gitnux.org/meth-addiction-recovery-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+21 additional datasets cited (not shown individually)